×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
PSNL – personalis, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
PSNL
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/20
08:19 am
psnl
Personalis, Inc. (NASDAQ: PSNL) had its price target raised by analysts at HC Wainwright from $9.00 to $11.00. They now have a "buy" rating on the stock.
Medium
Report
Personalis, Inc. (NASDAQ: PSNL) had its price target raised by analysts at HC Wainwright from $9.00 to $11.00. They now have a "buy" rating on the stock.
12/20
08:19 am
psnl
Personalis, Inc. (NASDAQ: PSNL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $7.25 price target on the stock.
Medium
Report
Personalis, Inc. (NASDAQ: PSNL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $7.25 price target on the stock.
12/19
09:07 am
psnl
Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna [Yahoo! Finance]
High
Report
Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna [Yahoo! Finance]
12/19
09:00 am
psnl
Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna
High
Report
Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna
12/16
08:07 am
psnl
Personalis and Tempus Expand Collaboration to Biopharma [Yahoo! Finance]
Low
Report
Personalis and Tempus Expand Collaboration to Biopharma [Yahoo! Finance]
12/16
08:00 am
psnl
Personalis and Tempus Expand Collaboration to Biopharma
Medium
Report
Personalis and Tempus Expand Collaboration to Biopharma
11/20
04:15 pm
psnl
Personalis to Participate at Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
Personalis to Participate at Upcoming Investor Conferences [Yahoo! Finance]
11/20
04:01 pm
psnl
Personalis to Participate at Upcoming Investor Conferences
Low
Report
Personalis to Participate at Upcoming Investor Conferences
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/19
09:06 am
psnl
Form 8-K Personalis, Inc. For: Dec 13
High
Report
Form 8-K Personalis, Inc. For: Dec 13
12/18
04:35 pm
psnl
Form 4 Personalis, Inc. For: Dec 16 Filed by: Chen Richard
High
Report
Form 4 Personalis, Inc. For: Dec 16 Filed by: Chen Richard
12/18
04:30 pm
psnl
Form 4 Personalis, Inc. For: Dec 16 Filed by: Moore Stephen Michael
High
Report
Form 4 Personalis, Inc. For: Dec 16 Filed by: Moore Stephen Michael
12/18
04:25 pm
psnl
Form 4 Personalis, Inc. For: Dec 16 Filed by: Tachibana Aaron
High
Report
Form 4 Personalis, Inc. For: Dec 16 Filed by: Tachibana Aaron
11/20
04:19 pm
psnl
Form 4 Personalis, Inc. For: Nov 18 Filed by: Tachibana Aaron
Medium
Report
Form 4 Personalis, Inc. For: Nov 18 Filed by: Tachibana Aaron
11/20
04:17 pm
psnl
Form 4 Personalis, Inc. For: Nov 18 Filed by: Moore Stephen Michael
Medium
Report
Form 4 Personalis, Inc. For: Nov 18 Filed by: Moore Stephen Michael
11/20
04:15 pm
psnl
Form 4 Personalis, Inc. For: Nov 18 Filed by: Chen Richard
Medium
Report
Form 4 Personalis, Inc. For: Nov 18 Filed by: Chen Richard
11/8
05:35 pm
psnl
Form SC 13G/A Personalis, Inc. Filed by: BlackRock, Inc.
Medium
Report
Form SC 13G/A Personalis, Inc. Filed by: BlackRock, Inc.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
6/19
Form 3 Personalis, Inc. For: Jun 19 Filed by: Abingworth LLP
20.2%
3/19 Form 4 Personalis, Inc. For: Mar 17 Filed by: West John Stephen 17.0%
3/27 Form 4 Personalis, Inc. For: Mar 25 Filed by: Chen Richard 16.6%
3/25 Form 8-K Personalis, Inc. For: Mar 25 10.1%
4/3 Form DEF 14A Personalis, Inc. For: May 15 8.7%
3/18 Form 4 Personalis, Inc. For: Mar 16 Filed by: Tachibana Aaron 8.3%
11/12 Personalis, Inc. Expands Oncology Portfolio With the Launch of Cancer Whole Genome Sequencing Services 7.0%
12/5 Form 4 Personalis, Inc. For: Dec 03 Filed by: Chen Richard 6.9%
4/9 Personalis (NASDAQ: PSNL) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.75 price target on the stock. 6.6%
4/23 Personalis to Announce First Quarter 2020 Financial Results on May 7, 2020 6.2%
3/19 Form 4 Personalis, Inc. For: Mar 17 Filed by: West John Stephen 17.0%
3/27 Form 4 Personalis, Inc. For: Mar 25 Filed by: Chen Richard 16.6%
3/25 Form 8-K Personalis, Inc. For: Mar 25 10.1%
4/3 Form DEF 14A Personalis, Inc. For: May 15 8.7%
3/18 Form 4 Personalis, Inc. For: Mar 16 Filed by: Tachibana Aaron 8.3%
11/12 Personalis, Inc. Expands Oncology Portfolio With the Launch of Cancer Whole Genome Sequencing Services 7.0%
12/5 Form 4 Personalis, Inc. For: Dec 03 Filed by: Chen Richard 6.9%
4/9 Personalis (NASDAQ: PSNL) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.75 price target on the stock. 6.6%
4/23 Personalis to Announce First Quarter 2020 Financial Results on May 7, 2020 6.2%
TOP News Decliners
8/13
Q2/2019 6/30/2019 EPS -0.890 ZacksConsensus -0.310 ActVsEst (0.580) - Miss
-18.0%
3/11 Personalis to Announce Fourth Quarter and Full Year 2019 Financial Results on March 25, 2020 -15.8%
9/26 Form 8-K Personalis, Inc. For: Sep 25 -15.6%
10/1 2 Top Stocks That Aren't on Wall Street's Radar [The Motley Fool] -13.2%
11/13 Form 10-Q Personalis, Inc. For: Sep 30 -11.6%
9/9 Personalis, Inc. Enters Into Research Agreement With Invectys to Provide Comprehensive Tumor Immunogenomics Profiling for Clinical Trial -11.5%
9/26 Personalis (NASDAQ: PSNL) was upgraded by analysts at Bank of America Corp from a "neutral" rating to a "buy" rating. -9.4%
11/17 Personalis, Inc. to Present New Data at the AACR Tumor Immunology and Immunotherapy Conference -8.7%
7/15 Personalis (NASDAQ: PSNL) is now covered by analysts at Bank of America Corp. They set a "neutral" rating on the stock. -6.8%
2/11 Form 4 Personalis, Inc. For: Feb 07 Filed by: LUDLUM KEN -5.8%
3/11 Personalis to Announce Fourth Quarter and Full Year 2019 Financial Results on March 25, 2020 -15.8%
9/26 Form 8-K Personalis, Inc. For: Sep 25 -15.6%
10/1 2 Top Stocks That Aren't on Wall Street's Radar [The Motley Fool] -13.2%
11/13 Form 10-Q Personalis, Inc. For: Sep 30 -11.6%
9/9 Personalis, Inc. Enters Into Research Agreement With Invectys to Provide Comprehensive Tumor Immunogenomics Profiling for Clinical Trial -11.5%
9/26 Personalis (NASDAQ: PSNL) was upgraded by analysts at Bank of America Corp from a "neutral" rating to a "buy" rating. -9.4%
11/17 Personalis, Inc. to Present New Data at the AACR Tumor Immunology and Immunotherapy Conference -8.7%
7/15 Personalis (NASDAQ: PSNL) is now covered by analysts at Bank of America Corp. They set a "neutral" rating on the stock. -6.8%
2/11 Form 4 Personalis, Inc. For: Feb 07 Filed by: LUDLUM KEN -5.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: